October 21, 2008
NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
ANN ARBOR, Mich., Oct. 21 /PRNewswire/ -- NanoBio Corporation announced today that it will present compelling new data in nine presentations that detail key milestones in its clinical and preclinical development programs in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal influenza vaccine during the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC, October 25-28.
The company's presentation schedule during the conference is detailed below. NanoBio will also exhibit at corporate booth #408.
Sunday, October 26, 2008
11:15 a.m. - 12:15 p.m. A Novel Nanoemulsion Adjuvant Enhancing the Immune Response to beta-propiolactone Inactivated Influenza Virus Using a Nasal Route in a Ferret Model, Poster #G-1194
Monday, October 27, 2008
11:15 a.m. - 12:15 p.m. Novel Nanoemulsion NB-001 Permeates Skin by the Follicular Route, Poster #A-1898
11:15 a.m. - 12:15 p.m. NB-002, a Novel Nanoemulsion with Anti-Dermatophyte Activity, Poster #M-2134
11:15 a.m. - 12:15 p.m. Mechanism of Skin Penetration and Distribution of a Novel Nanoemulsion, Poster #M-2135
12:15 p.m. - 1:15 p.m. Safety, Tolerability and Pharmacokinetics of NB-001 in a Phase 2 Dose-Ranging Trial in Subjects with Recurrent Herpes Labialis, Presentation #V-3539
12:15 p.m. - 1:15 p.m. NB-001, A Novel Nanoemulsion Active Against Acyclovir (ACV)- and Foscarnet (FOS)-Resistant Herpes Simplex Virus (HSV) 1 and 2, Poster #V-3538
Tuesday, October 28, 2008
9:00 a.m. - 9:15 a.m. Oral Presentation: Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis
11:15 a.m. - 12:15 p.m. Novel Nanoemulsion Antimicrobials Tested Against Nine Gram-Positive Species, Poster #F1-3944
11:15 a.m. - 12:15 p.m. Antimicrobial Activity of Nanoemulsions Tested Against Seven Gram-Negative Species, Poster #F1-3945
NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company headquarters and laboratory facilities are located in Ann Arbor, Mich.
CONTACT: John Coffey, Vice President, Business Development of NanoBioCorporation, +1-734-302-9107, or [email protected]